Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6926MR)

This product GTTS-WQ6926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6926MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1501MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ1552MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ6528MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ13444MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ9787MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ2853MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ13643MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ8077MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW